CORAL GABLES, Fla., March 26, 2025 (GLOBE NEWSWIRE) — Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, or “the Company”), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Thursday, March 27, 2025 at 4:30 PM ET to discuss recent business progress and financial results for the fourth quarter ended December 31, 2024.
Conference Call and Webcast Information:
A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies that have the potential to bring meaningful clinical benefits to targeted patient populations.
Lead investigational program, NDV-01, for High-Grade Non-Muscle Invasive Bladder Cancer, is being evaluated in a Phase 2 study. In addition, preparations are underway to advance sepranolone, a Phase 2b-ready investigational program for compulsion-related disorders including Tourette’s Syndrome into further studies.
For more information, visit www.relmada.com.
Investor Contact:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
Media Inquiries:
Corporate Communications
media@relmada.com
The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix,…
VANCOUVER, BC / ACCESS Newswire / December 22, 2025 / 1933 Industries Inc. (the "Company"…
Partnership to expand access to personalized primary care, including same-day appointments and mental health services,…
Novel PTH analog achieves sustained calcium elevation for >3 days from single oral tablet, supporting…
MINNEAPOLIS, Dec. 22, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical…
-Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28…